Which future for aspirin in acute coronary syndromes treated with percutaneous coronary intervention? An overview on aspirin-free strategies.

Authors:
Spadafora L; Bernardi M; Galli M; Biondi-Zoccai G; Sabouret P.

Journal:
Arch Med Sci

Publication Year: 2022

DOI:
10.5114/aoms/155411

PMCID:
PMC9710287

PMID:
36457983

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Arch Med Sci

Abbreviation: Arch Med Sci

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Medicine, General & Internal

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Atypical presentation of Lyme disease.
Jarosińska A; Pilśniak A; Cieśla-Fuławka A and 3 more (2024) - Transparency Score: 2/6
Cuproptosis-related genes are involved in immunodeficiency following ischemic stroke.
Jinshi L; Cong Y; Liang S and 2 more (2024) - Transparency Score: 3/6
Efficacy of ornidazole for pericoronitis: a meta-analysis and systematic review.
Du R; Ba K; Yang Y and 2 more (2024) - Transparency Score: 2/6
Interleukins: pathophysiological role in acute pancreatitis.
Rafaqat S; Patoulias D; Behnoush AH and 2 more (2024) - Transparency Score: 3/6
Level of basic hope and symptoms of anxiety and depression in women after miscarriage.
Białek K; Sadowski M; Adamczyk-Gruszka O and 2 more (2024) - Transparency Score: 2/6
View All Papers from This Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of interest Giuseppe Biondi-Zoccai has consulted for Balmed, Cardionovum, Crannmedical, Eukon, Innovheart, Guidotti, Meditrial, Microport, Opsens Medical, Replycare, Teleflex, and Terumo. Pierre Sabouret reports consulting fees paid by Astra Zeneca, Amgen, BI, BMS, Lilly, Novartis, Sanofi, Servier, Vifor outside the submitted work."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025